tetano
Editor, Senior Moderator
Nat Commun
. 2023 Mar 28;14(1):1734.
doi: 10.1038/s41467-023-37422-y.
mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5
Emanuele Andreano[SUP] 1 [/SUP], Ida Paciello[SUP] 1 [/SUP], Giulio Pierleoni[SUP] 2 [/SUP], Giuseppe Maccari[SUP] 3 [/SUP], Giada Antonelli[SUP] 1 [/SUP], Valentina Abbiento[SUP] 1 [/SUP], Piero Pileri[SUP] 1 [/SUP], Linda Benincasa[SUP] 2 [/SUP], Ginevra Giglioli[SUP] 2 [/SUP], Giulia Piccini[SUP] 4 [/SUP], Concetta De Santi[SUP] 1 [/SUP], Claudia Sala[SUP] 1 [/SUP], Duccio Medini[SUP] 3 [/SUP], Emanuele Montomoli[SUP] 2 4 5 [/SUP], Piet Maes[SUP] 6 [/SUP], Rino Rappuoli[SUP] 7 8 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome 2 Omicron BA.4 and BA.5 are characterized by high transmissibility and ability to escape natural and vaccine induced immunity. Here we test the neutralizing activity of 482 human monoclonal antibodies isolated from people who received two or three mRNA vaccine doses or from people vaccinated after infection. The BA.4 and BA.5 variants are neutralized only by approximately 15% of antibodies. Remarkably, the antibodies isolated after three vaccine doses target mainly the receptor binding domain Class 1/2, while antibodies isolated after infection recognize mostly the receptor binding domain Class 3 epitope region and the N-terminal domain. Different B cell germlines are used by the analyzed cohorts. The observation that mRNA vaccination and hybrid immunity elicit a different immunity against the same antigen is intriguing and its understanding may help to design the next generation of therapeutics and vaccines against coronavirus disease 2019.
. 2023 Mar 28;14(1):1734.
doi: 10.1038/s41467-023-37422-y.
mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5
Emanuele Andreano[SUP] 1 [/SUP], Ida Paciello[SUP] 1 [/SUP], Giulio Pierleoni[SUP] 2 [/SUP], Giuseppe Maccari[SUP] 3 [/SUP], Giada Antonelli[SUP] 1 [/SUP], Valentina Abbiento[SUP] 1 [/SUP], Piero Pileri[SUP] 1 [/SUP], Linda Benincasa[SUP] 2 [/SUP], Ginevra Giglioli[SUP] 2 [/SUP], Giulia Piccini[SUP] 4 [/SUP], Concetta De Santi[SUP] 1 [/SUP], Claudia Sala[SUP] 1 [/SUP], Duccio Medini[SUP] 3 [/SUP], Emanuele Montomoli[SUP] 2 4 5 [/SUP], Piet Maes[SUP] 6 [/SUP], Rino Rappuoli[SUP] 7 8 [/SUP]
Affiliations
- PMID: 36977711
- DOI: 10.1038/s41467-023-37422-y
Abstract
Severe acute respiratory syndrome 2 Omicron BA.4 and BA.5 are characterized by high transmissibility and ability to escape natural and vaccine induced immunity. Here we test the neutralizing activity of 482 human monoclonal antibodies isolated from people who received two or three mRNA vaccine doses or from people vaccinated after infection. The BA.4 and BA.5 variants are neutralized only by approximately 15% of antibodies. Remarkably, the antibodies isolated after three vaccine doses target mainly the receptor binding domain Class 1/2, while antibodies isolated after infection recognize mostly the receptor binding domain Class 3 epitope region and the N-terminal domain. Different B cell germlines are used by the analyzed cohorts. The observation that mRNA vaccination and hybrid immunity elicit a different immunity against the same antigen is intriguing and its understanding may help to design the next generation of therapeutics and vaccines against coronavirus disease 2019.